These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18804387)

  • 1. Development of a novel recombinant influenza vaccine in insect cells.
    McPherson CE
    Biologicals; 2008 Nov; 36(6):350-3. PubMed ID: 18804387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FluBlok, a recombinant influenza vaccine.
    Huber VC; McCullers JA
    Curr Opin Mol Ther; 2008 Feb; 10(1):75-85. PubMed ID: 18228185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fast track influenza virus vaccine produced in insect cells.
    Cox MM; Hashimoto Y
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S31-41. PubMed ID: 21784229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process.
    Buckland B; Boulanger R; Fino M; Srivastava I; Holtz K; Khramtsov N; McPherson C; Meghrous J; Kubera P; Cox MM
    Vaccine; 2014 Sep; 32(42):5496-502. PubMed ID: 25131727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
    Arnoux S; Weinberger C; Gessner BD
    Vaccine; 2007 Nov; 25(45):7720-31. PubMed ID: 17920168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.
    Wu Q; Fang L; Wu X; Li B; Luo R; Yu Z; Jin M; Chen H; Xiao S
    Mol Immunol; 2009 Jul; 46(11-12):2210-7. PubMed ID: 19446339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-based protein vaccines for influenza.
    Cox MM
    Curr Opin Mol Ther; 2005 Feb; 7(1):24-9. PubMed ID: 15732526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.
    Safdar A; Cox MM
    Expert Opin Investig Drugs; 2007 Jul; 16(7):927-34. PubMed ID: 17594180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative influenza vaccines made by insect cells.
    Krammer F; Grabherr R
    Trends Mol Med; 2010 Jul; 16(7):313-20. PubMed ID: 20570562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of cell culture-based influenza vaccine production.
    Perdue ML; Arnold F; Li S; Donabedian A; Cioce V; Warf T; Huebner R
    Expert Rev Vaccines; 2011 Aug; 10(8):1183-94. PubMed ID: 21854311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza virus-like particle vaccines.
    Haynes JR
    Expert Rev Vaccines; 2009 Apr; 8(4):435-45. PubMed ID: 19348559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a vaccine against pandemic influenza viruses: current status and perspectives.
    Ilyinskii PO; Thoidis G; Shneider AM
    Int Rev Immunol; 2008; 27(6):392-426. PubMed ID: 19065349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of a novel influenza vaccine derived from a continuous cell line].
    Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.